93 results about "Ophthalmic preparations" patented technology

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

The invention provides gelatin derivative microspheres coated with stem cell exosomes, a preparation method of the gelatin derivative microspheres and application of the gelatin derivative microspheres in preparation of external ophthalmic preparations, and relates to the technical field of medicines. The gelatin derivative microsphere mainly comprises a microsphere core and a shell, wherein the microsphere core is a stem cell exosome coated with a gelatin derivative; the shell is obtained by crosslinking a gelatin derivative and sodium hyaluronate. The gelatin derivative used in the invention not only has good compatibility with the stem cell exosome, but also has good dispersibility in tears or periorbital secretion after being prepared by crosslinking the gelatin derivative and sodium hyaluronate, so that the elimination of an eye protection mechanism to the microspheres can be reduced, and the slow release effect of the exosome can be improved; besides, the shell formed by the hyaluronic acid has a very good tackifying effect, so that the retention time of the gelatin derivative hyaluronic acid microspheres in eyes is prolonged, and the problem of burst release of the medicine is also avoided by virtue of the double-layer coated microsphere structure.

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

The present application relates to an ophthalmic preparation and use thereof. Specifically, the present application relates to an ophthalmic preparation of pilocarpine and use thereof for treating eye diseases. The ophthalmic preparation of pilocarpine provided by the present application has the beneficial effects of good stability and less eye irritation.

The present invention relates to ophthalmic formulations in which a synergistic combination of three different types of disinfectants (a polybiguanide compound, a quaternary ammonium compound and an antifungal / anti-acanthamoeba compound), in particular a combination of polyhexamethylene biguanide, polyquaternium-1 and myristoylaminopropyl dimethylamine, high concentrations of hyaluronates are enabled to provide better comfort and support for corneal health without compromising antimicrobial efficacy. The novel ophthalmic formulations support the use of hyaluronates at concentrations greater than 7.5 times as high as currently commercially available multi-purpose disinfectants.

The invention discloses an ophthalmic preparation and application thereof. The ophthalmic preparation comprises a TNF alpha nano antibody, a protective agent, a thickening agent, a buffer solution and an optional surfactant, and pH lt is larger than or equal to 6.0 and smaller than or equal to 0; 7, 7; the protective agent is selected from at least one of trehalose, mannitol, arginine and glycine; the thickening agent is selected from any one of hydroxypropyl methyl cellulose, polyvinyl alcohol and sodium hyaluronate; the buffer solution is a phosphate buffer solution or a histidine buffer solution. The ophthalmic formulations are useful in the treatment of immune-mediated inflammatory ophthalmic diseases.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The present invention relates to the field of therapy and drug delivery. More specifically, therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-protected organs that harbor substantial populations of postmittal neurons, such as organs derived from the neural tube, including the central nervous system and the eye. The disclosed methods and compositions involve topical administration of an effector component that targets intracellular biological targets to such organs, in combination with a saponin component that enhances the effective uptake of the effector component into cells and / or enhances the effective delivery of the effector component within cells where the biological target is present. For example, the effector component may be an oligonucleotide therapeutic that targets gene products associated with CNS and / or ocular disorders. Due to the cellular uptake stimulating and / or endosomal escape enhancing effects of the saponin component, the neuropharmaceuticals and ophthalmic compositions presented herein for topical administration to the CNS and / or eye, respectively, can be formulated with lower concentrations of the effector component and / or lower volumes, which provides safety benefits to neurons and patient comfort.

An ophthalmic composition for treating non-infectious inflammatory diseases. The ophthalmic composition comprises an active substance and an ophthalmic excipient, wherein the active substance is a JAK inhibitor; and the ophthalmic excipient comprises a pH buffer, an osmotic pressure regulator, a solubilizer, and water for injection. The ophthalmic composition is used for topical eye drop administration, is compatible and stable with eyes, can improve the bioavailability of the active substance in the ophthalmic composition, can be used for treating non-infectious inflammatory diseases, is less invasive, has small side effects, involves a simple production process, and is amenable to large-scale production.

The invention provides stable ophthalmic formulations, a unit dose containing such formulations, medical kits, and methods for making and using such formulations and unit doses to treat patients suffering from a disorder mediated by an αv integrin, such as diabetic retinopathy.

A noninvasive ophthalmic formulation, comprising a chelator (such as EDTA and its salts), a transport enhancer (such as Methyl Sulfonyl Methane; MSM), a second polyoxyalkylene permeation enhancer such as propylene glycol capable of enhancing permeation through lipid-thickened ocular membranes, a thickening agent such as hydroxyethyl cellulose (HEC) and a surfactant such as polysorbate 80, is provided. The novel combination of the ingredients unexpectedly and beneficially reduces symptoms associated with early-stage, age-related cataracts. Methods for treating cataracts with compositions of the invention and measurement of improved visual function by measuring contrast sensitivity (CS) are provided.

The present invention relates to ophthalmic formulations wherein a synergistic combination of three different classes of disinfectants (a multimeric biguanide compound, a quaternary ammonium compound and an antifungal / anti-acanthamoeba compound, in particular a combination of polyhexamethylene biguanide, Polyquaternium-1 and myristamidopropyl dimethylamine) enables the use of high concentrations of hyaluronate for providing better comfort and support of corneal health without compromising antimicrobial efficacy. The novel ophthalmic formulations support the use of more than 7.5 times higher concentrations of hyaluronate than are present in currently marketed multi-purpose disinfection solutions.

To provide a novel ophthalmic composition comprising diquafosol or a salt thereof.SOLUTION: There is provided an ophthalmic composition comprising diquafosol or a salt thereof and a cationic polymer, wherein the cationic polymer is at least one selected from the group consisting of chitosan, a chitosan derivative, a cationic (meth)acrylate copolymer, a cationic silicone polymer, a diallyl quaternary ammonium salt / acrylamide copolymer, cationic hydrolyzed keratin, cationic hydrolyzed silk, cationic hydrolyzed collagen, cationic hydrolyzed casein, cationic hydrolyzed soybean protein, a cationic vinylpyrrolidone copolymer, polyvinylpyrrolidone, homopolymers of dimethyl diacrylic ammonium chloride, an adipic acid / dimethylaminohydroxypropyl diethylenetriamine copolymer, an adipic acid / epoxy propyldiethylenetriamine copolymer and an acrylamide / β-methacroyloxyethyltrimethylammonium methyl sulfate copolymer.SELECTED DRAWING: None

The present invention relates to a protein tyrosine kinase inhibitor and an ophthalmic preparation thereof. The protein tyrosine kinase inhibitor not only effectively antagonizes the activity of a VEGFR receptor tyrosine kinase, but also improves the pharmacokinetic properties thereof, while exhibiting high selectivity in inhibiting the activity of an "off-target" EGFR tyrosine kinase, thereby reducing or avoiding side effects, particularly those affecting the eyes. The preparation can greatly improve the solubility of the protein tyrosine kinase inhibitor compound, prolong the residence time of the compound on the ocular surface, increase exposure in fundus tissue, and improve the bioavailability.

A solubilizing composition for the poorly soluble drug rebamipide, its preparation method and application, and the solubilizing method, by combining rebamipide with a phosphorylated drug in a specific ratio, effectively improves the solubility of rebamipide in PBS. The solubilizing composition prepared by this invention significantly improves the bioavailability of rebamipide, providing a new approach for the development of oral and ophthalmic formulations of rebamipide.

Ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast formulated with optimized viscosity and are suitable for intravitreal or other forms of ocular administration. The compositions can improve drug administration and absorption, distribution, metabolism, and excretion (ADME) properties. The ophthalmic pharmaceutical formulations can be administered via intravitreal injection resulting in the formation of a depot in the vitreous. The depot can remain in the vitreous for a prolonged period of time resulting in therapeutic drug levels over this period of time and improved durability.

The invention discloses a small-molecule active aldehyde scavenger-albumin coupling medicine as well as a preparation method and application of the small-molecule active aldehyde scavenger-albumin coupling medicine. The coupling drug comprises a) the small molecule active aldehyde scavenger compound or the derivative thereof and b) albumin, and the albumin comprises at least one of human serum albumin, recombinant albumin, bovine serum albumin, ovalbumin and mouse serum albumin. The medicine is further prepared into an ophthalmic preparation, the retention time of the medicine in the cornea is prolonged, the in-vitro active aldehyde removal efficiency of the medicine is improved to 1.5 times of that of NS-2, expression (larger than or equal to 50%) of a human corneal epithelial cell inflammatory factor IL-6 is remarkably inhibited, and irritation to eyes is avoided. Through the synergistic effect of long-acting slow release of the albumin carrier and targeted removal of NS, the technical defects that a traditional xerophthalmia medicine is short in effect and single in mechanism are overcome, and a definite clinical transformation value is achieved.

To provide an appropriate ophthalmic composition for treatment of dry eye syndrome using Tanfanercept.SOLUTION: Provided is an ophthalmic composition comprising Tanfanercept as an active ingredient for treating dry eye syndrome in a patient having moderate to severe dry eye.SELECTED DRAWING: Figure 26

To provide a novel ophthalmic composition. [Solution] The ophthalmic composition is composed of (A) one or more selected from the group consisting of pranoprofen and its salts, and (B) one or more selected from the group consisting of epinastine and its salts.

The invention relates to ophthalmic compositions comprising thiol drugs, such as cysteamine, for the prevention and / or treatment of ocular conditions related to the hardening and / or opacification of the crystalline lens of the eye; for instance, ocular conditions such as cataracts and presbyopia.

The present invention relates to an eye drop composition comprising imatinib. The present invention relates to an eye drop composition and a method for preparing same, in which the eye drop composition is prepared at a pH level suitable as an eye drop while an appropriate amount of an imatinib derivative is dissolved even within a relatively high pH range, compared to conventional compositions prepared under pH conditions (< pH 5.5) unsuitable for eye drop, in order to dissolve imatinib, and has improved phase stability, long-term stability, bioavailability, and eye irritation.

The invention belongs to the field of ophthalmic polypeptides and drugs thereof, and provides an ophthalmic fusion polypeptide with a xerophthalmia relieving effect and an antibacterial effect at the same time, and an ophthalmic preparation containing the polypeptide. The ophthalmic fusion polypeptide provided by the invention has an antibacterial effect, and can reduce or eliminate the use of an antibacterial agent in a preparation, so that the prepared preparation has small irritation and is safer and more effective.

The present invention relates to the technical field of medicine, and in particular to a use of bencycloquidium bromide, an isomer thereof and a derivative thereof in the preparation of a drug for preventing or treating an ophthalmic disease. Moreover, the present invention provides an ophthalmic formulation using the bencycloquidium bromide, the isomer thereof and the derivative thereof as active ingredients. According to the present invention, by using the bencycloquidium bromide, the isomer thereof and the derivative thereof in eyes, it is discovered that the bencycloquidium bromide, the isomer thereof and the derivative thereof have an obvious inhibitory effect on changes in ocular axial length and diopter in the progression process of a myopic refractive error, and then it is discovered that the ophthalmic formulation using the bencycloquidium bromide, the isomer thereof and the derivative thereof as active ingredients has significant advantages in the prevention and treatment of ophthalmic diseases, especially in preventing myopia and slowing down the progression of myopia, etc.

The invention discloses application of an ophthalmic preparation containing a recombinant human beta-nerve growth factor. The ophthalmic preparation can be used for treating dry eyes. The ophthalmic preparation containing the recombinant human beta-nerve growth factor comprises 5 to 1000 [mu] g / ml of the recombinant human beta-nerve growth factor, 20 to 70 mg / ml of trehalose, 5 to 30 mg / ml of mannitol and 1 to 13 mg / ml of polyvinyl alcohol.

The present invention relates to ophthalmic formulations comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide or a pharmaceutically acceptable salt thereof, to methods for preparation thereof, and uses thereof for treatment of various eye conditions (e.g., pain).

The present disclosure provides an ophthalmic formulation comprising: one or more pharmaceutically acceptable excipients; a pharmaceutically active compound capable of reducing the amount or deleterious effects of autoantibodies on the ocular surface, such as IgG; in particular, the present disclosure provides an ophthalmic formulation wherein the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular diseases that can cause symptoms of ocular discomfort, keratitis, dry eye disease, formation of symblepharon, shortening of the anterior chamber depth, lid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.

The application discloses an ophthalmic preparation and application thereof, and belongs to the technical field of ophthalmic preparations. The ophthalmic preparation comprises the following components: recombinant human beta nerve growth factor, hydrochloric acid histidine or citrate, polyvinyl alcohol or hydroxypropyl methyl cellulose, L-methionine, and a protective agent, wherein the protective agent is selected from one or more of trehalose, glycerol and amino acids; and the pH value of the ophthalmic preparation is 6.0-7.0. The ophthalmic preparation has good storage stability.

The invention discloses a preparation method of eye sustained-release eye drops. The preparation method comprises the following steps: step 1, preparing cyclodextrin microspheres; step 2, preparing cyclodextrin microspheres loaded with atropine sulfate; and step 3, dispersing the atropine sulfate loaded cyclodextrin microspheres obtained in the step 2 in deionized water to obtain a mixed solution, then adding a thickening agent, mannitol and benzalkonium chloride, and stirring at room temperature for 20-30 minutes to obtain the eye sustained-release eye drops. The invention further discloses the eye sustained-release eye drops prepared by the preparation method and application of the eye sustained-release eye drops. The sustained-release eye drops for eyes have the advantages of high stability, high bioavailability, low irritation and controllable release rate.